Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

European Respiratory Journal

Volumn 20, Issue 1, 2002, Pages 73-78

  Buhl, R ^a   Soler M ^a   Matz, J ^a   Townley, R ^a   O'Brien, J ^a   Noga, O ^a   Champain, K ^a   Fox, H ^a   Thirlwell, J ^a   Della Cioppa, G ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Allergic asthma; Anti immunoglobulin E antibody; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE; STEROID; TRIAMCINOLONE ACETONIDE; XANTHINE DERIVATIVE; ANTIASTHMATIC AGENT; BECLOMETASONE; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EYE DISEASE; FEMALE; GENITAL SYSTEM DISEASE; HUMAN; INCIDENCE; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; UROGENITAL TRACT DISEASE; XEROSTOMIA; ASTHMA; CHILD; FOLLOW UP; HOSPITALIZATION; HYPERSENSITIVITY; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BECLOMETHASONE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN; HYPERSENSITIVITY; MALE; MIDDLE AGE; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035989332     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00278102     Document Type: Article

References (19)

1. British guidelines on asthma management: 1995 review and position statement
2. Should anti-inflammatory agents be used earlier in asthma?
3. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma
4. Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study
5. Asthma
6. Association of asthma with serum IgE and skin-test reactivity to allergens
7. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children
8. Total serum IgE and its association with asthma symptoms and allergic sensitization among children
9. Update on cytokines
10. Updates on cells and cytokines: The human mast cell
11. Omalizumab
12. The binding site on human immunoglobulin E for its high affinity receptor
13. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
14. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
15. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics
16. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects
17. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
18. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis